3 completed, 2 withdrawn, 1 unknown. 6 Phase 2, 1 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 6 | Completed 3, Withdrawn 2, Unknown 1 |
| Phase 1 | 1 | Withdrawn 1 |
Follow GCS-100: new trials by email Literature Review of GCS-100 trials Research Report on GCS-100
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Phase 2b Study of GCS-100 in Patients With Chronic Kidney Disease Caused by Diabetes GCS-100, Placebo - Diabetic Chronic Kidney Disease | Phase 2 | Unknown | La Jolla Pharmaceutical Company | 375 | 2015-03-01 | 2015-05-19 |
| A Phase 2 Extension of Study GCS-100-CS-4003 GCS-100 - Chronic Kidney Disease | Phase 2 | Withdrawn | La Jolla Pharmaceutical Company | 2015-01-01 | 2015-01-15 | |
| A Phase 2 Extension Study of Study GCS-100-CS-4002 GCS-100 - Chronic Kidney Disease | Phase 2 | Completed | La Jolla Pharmaceutical Company | 92 | 2014-01-01 | 2016-12-26 |
| A Phase 2a Study of Weekly Doses of GCS-100 in Patients With Chronic Kidney Disease GCS-100, Placebo, Saline - Chronic Kidney Disease | Phase 2 | Completed | La Jolla Pharmaceutical Company | 120 | 2013-06-01 | 2015-09-01 |
| GCS-100LE in Combination With Etoposide and Dexamethasone in Relapsed or Refractory Diffuse Large B-Cell Lymphoma GCS-100, Etoposide; Dexamethasone - Diffuse Large B-cell Lymphoma | Phase 1 / Phase 2 | Withdrawn | La Jolla Pharmaceutical Company | 2008-07-01 | 2013-06-25 | |
| Study of the Safety of GCS-100 in Subjects With Chronic Lymphocytic Leukemia GCS-100 - Chronic Lymphocytic Leukemia | Phase 2 | Completed | La Jolla Pharmaceutical Company | 12 | 2007-02-01 | 2013-06-17 |
Renal Insufficiency, Chronic (3) · Leukemia (1) · Leukemia, Lymphocytic, Chronic, B-Cell (1) · Lymphoma, Large B-Cell, Diffuse (1) · Neoplasms (1) · Recurrence (1)
La Jolla Pharmaceutical Company (6)
United States (6)
George Tidmarsh, MD, PhD (3) · David Smith, MD (1) · George F Tidmarsh, MD, PhD (1) · Lauren Pinter-Brown, MD (1)